[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mpmri\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mpmri":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100608537","early-prediction-of-neoadjuvant-chemotherapy-response-in-bladder-cancer-using-quantitative-multiparametric-mri-100608537",false,"NCT07202845","Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI","mpMRI","Inclusion Criteria:\n\n* Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements.\n* Planned to receive cisplatin-based NAC followed by radical cystectomy.\n* Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC).\n\nExclusion Criteria:\n\n* Patients who have received pelvic radiotherapy.\n* Severe renal impairment\n* Previous open or laparoscopic pelvic surgery.\n* Presence of distant metastases at diagnosis.\n* Patients with contraindications to MRI.\n* Ineligibility to cisplatin","ALL","18 Years",{"count":19,"type":20},39,"ESTIMATED","OBSERVATIONAL","Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.",[24,14,25],"MIBC","NAC",[27],"ultiparametric MRI, mpMRI, Diffusion-Weighted Imaging, DWI","RECRUITING","2025-09-24",{"date":31,"type":32},"2025-10-02","ACTUAL",{"date":34,"type":32},"2025-08-29",{"date":36,"type":20},"2026-06-01",{"name":38,"class":39},"Assiut University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100585371","the-diagnostic-application-of-psmapetmr-in-patients-undergoing-secondary-prostate-puncture-100585371","NCT06901492","The Diagnostic Application of PSMAPET\u002FMR in Patients Undergoing Secondary Prostate Puncture","The Diagnostic Application of PSMA PET\u002FMR in Patients with PSA \u003C20 Ng\u002Fml and Initial Negative Prostate Biopsy","Inclusion Criteria:\n\n1. Age ≥40 years, male;\n2. Serum PSA level 4-20 ng\u002FmL;\n3. Serum PSA level 4-20 ng\u002FmL;\n4. No contraindications to PSMA-PET\u002FCT or MRI;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Serum PSA \\>20 ng\u002FmL;\n2. History of prostate surgery\u002Fradiotherapy;\n3. Acute prostatitis;\n4. Coagulation disorders or active infection;\n5. Severe internal\u002Fexternal hemorrhoids, perianal, rectal, or gluteal lesions;\n6. Allergy to local anesthetics;\n7. Inability to tolerate the biopsy procedure.","MALE","40 Years",{"count":51,"type":20},120,"INTERVENTIONAL",[54],"NA","The present study is designed to explore the value of targeted puncture guided by PSMA PET\u002FCT or mpMRI in the diagnosis of patients with low PSA and initial negative prostate biopsy",[57,58,59],"PSMA PET\u002FCT","Prostate Cancer","MpMRI",[61,57,14,62],"Prostate cancer","Prostate biopsy","NOT_YET_RECRUITING","2025-03-23",{"date":66,"type":32},"2025-03-30",{"date":68,"type":20},"2025-06-01",{"date":70,"type":20},"2028-06-01",{"name":72,"class":39},"Nanjing First Hospital, Nanjing Medical University"]